Overview

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Status:
Recruiting
Trial end date:
2025-02-10
Target enrollment:
Participant gender:
Summary
Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University